Compare eBay Inc (EBAY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Viatris Inc — how do they compare? eBay Inc trades at $112.73 (market cap $50.07B), while Viatris Inc trades at $17.05 (market cap $19.44B). The key difference: eBay Inc is far larger — about 2.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| EBAY | VTRS | |
|---|---|---|
Market Cap | $50.07B | $19.44B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $17.39 |
52-Week Low | $76.79 | $8.74 |
Enterprise Value | $53.41B | $31.65B |
Dividend Yield | 1.1% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $112.54, down 2.22% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters with Q1 2026 EPS of $1.66 beating expectations of $1.58. Revenue growth accelerated to $11.1B in 2025, while maintaining robust profitability with 71.79% gross margins and 17.61% net income margin. Recent developments include the UK regulator clearing eBay's acquisition of Depop and ongoing market speculation about GameStop's takeover interest.
EBAY presents a mixed investment case with strong fundamentals offset by acquisition uncertainty. The stock trades above analyst consensus target of $108.78 despite recent weakness. Key opportunities include continued earnings momentum and advertising revenue growth, while risks center on competitive pressures and potential takeover volatility. Institutional sentiment remains cautiously optimistic with 46% buy ratings.
Viatris (VTRS) trades at $16.31, down 0.49% on the day, with technical indicators showing a bullish moving average trend despite recent price weakness. The company has beaten earnings expectations for three consecutive quarters, though it reported a significant net loss of -$3.51B in 2025. Analyst consensus leans toward 'Hold' with a $20 price target, representing 22.6% upside potential. Recent positive developments include FDA acceptance of its fast-acting meloxicam NDA and promising Phase 3 results for VR-205 in Japan.
The outlook presents a value recovery opportunity with reasonable valuation metrics (P/S: 1.34, P/B: 1.33) and improving cash flow trends, but significant risks remain including persistent negative profitability margins, high debt levels, and intense generic drug competition. The stock's direction will depend on successful pipeline execution and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
